Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis.
CONCLUSIONS: Over 75% of patients with MDS failed HMA-treatment within 6 months of initiation and were observed with more inpatient admissions than those with HMA-treatment success, translating into substantially higher healthcare costs. HMA-treatment failure results in an important economic burden in MDS patients.
PMID: 33472483 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Economics | Health Management | Healthcare Costs | Laboratory Medicine | Leukemia | Medicare | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study | Transplants